Disruptions to hit M&A, financing (ICIS Chemical Business December 2 – December 8, 2022)
Young & Partners shows that global disruptions and uncertainties are suppressing M&A, Stock Prices and Financings.
Chemical M&A trends shift down (ICIS Chemical Business August 26 – September 1, 2022)
Young & Partners shows that global disruptions and uncertainties are suppressing M&A, Stock Prices and Financings.
Pharm Exec: Navigating the Financial Meltdown for Biopharma (Young & Partners article – August 2022 issue)
A review of pharma and biotech equity market, IPO, and M&A trends and disruptions through the first half of 2022 and the implications for the future.
Structural Changes and Disruptions (ICIS Chemical Business April 8 – April 21 2022)
Young & Partners covers the changes the chemical industry is facing now and will face in the future
Pharm Exec: Biopharma in 2021 Big Gains, Volatile Values (Young & Partners article – March 2022)
Young & Partners View of the Strategic, M&A and Financial trends in 2021 and outlook
Pharm Exec: China Invests in Building Biotech (Young & Partners comments – January 2022)
Young & Partners comments on what to expect from China in this article
Chemicals M&A to be resilient in 2022 (ICIS Chemical Business February 11 – February 17 2022)
Young & Partners reviews the developments through yearend and the outlook for 2022
New Supply Chains (ICIS Chemical Business November 26 – December 2 2021)
Takeaways from Senior Chemical Executive Conference Panel on Reimagining Supply Chain Strategies
Chemical Economic, M&A and Financing (ICIS Chemical Business November 19-26 2021)
Comprehensive look at the economic, stock market, M&A and financing trends and outlook
Pharm Exec: Doubling Down On Innovation, Recovery (Young & Partners article – September 2021)
While activity and outputs have been mixed, and pandemic challenges linger on, the outlooks for pharma and biotech remain stable